WORCESTER, Mass., March 16, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).
